Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review
Frontiers in Pharmacology · 10.07.2026 · 17
DOI: 10.3389/fphar.2026.1877033 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.07.2026. Verfasst von Hala Altaher und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine (CoM), Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health, Dubai, United Arab Emirates. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Infliximab (IFX) is a chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-α) that is widely used for induction and maintenance therapy in pediatric inflammatory bowel disease (IBD), yet its effects on the developing intestinal microbiome and treatment response remain unclear.
Objective
To systematically synthesize evidence on IFX-associated microbiome changes in pediatric IBD and evaluate microbiome features linked to treatment response.
Methods
A systematic review was conducted following the PRISMA 2020 guidelines. PubMed, Scopus, Embase, and CENTRAL were searched from database inception until March 2026, and our results were synthesized narratively.
Results
Of the 945 records identified, 13 studies met the inclusion criteria, comprising 242 pediatric patients. Findings for alpha diversity were variable across studies. In contrast, beta-diversity patterns, taxonomic profiles, and functional analyses more consistently showed positive IFX-associated microbial changes. Responders to treatment more frequently showed enrichment of beneficial taxa, including Faecalibacterium, Subdoligranulum, and Bifidobacterium , while non-responders exhibited a tendency towards dysbiotic microbial signatures, evidenced by increased levels of Gammaproteobacteria and Candida . Functional and metabolomic studies suggested beneficial shifts in bile-acid metabolism, short-chain fatty acid-related pathways, and inflammatory signaling post IFX treatment. Clinical and biochemical improvements with IFX were consistently reported; however, these improvements were not always accompanied by uniform recovery of overall microbial diversity.
Conclusion
In pediatric IBD, IFX is more consistently associated with shifts in microbial composition and function than with broad increases in overall microbial diversity. Further large, standardized studies are warranted to refine the role of microbiome features in biologic treatment stratification. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251133625 , identifier CRD420251133625.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine (CoM), Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health, Dubai, United Arab Emirates.
Zitieren
APA
Altaher, H., Al-Mashhadani, M., Usman, R., Ghelani, H., & Jan, R. K. (2026). Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1877033
Vancouver
Altaher H, Al-Mashhadani M, Usman R, Ghelani H, Jan RK. Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1877033
BibTeX
@article{Altaher2026,
author = {Altaher, Hala and Al-Mashhadani, Mustafa and Usman, Rameen and Ghelani, Hardik and Jan, Reem K},
title = {Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1877033}
}
EUVIMED